James L Boyer
Overview
Explore the profile of James L Boyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
135
Citations
3743
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jeong J, Hsu S, Horikami D, Utsumi T, Yang Y, Arefyev N, et al.
bioRxiv
. 2025 Jan;
PMID: 39868144
The liver lymphatic system plays a critical role in maintaining interstitial fluid balance and immune regulation. Efficient lymphatic drainage is essential for liver homeostasis, but its role in liver disease...
2.
Hayes C, Gallucci G, Boyer J, Assis D, Ghonem N
Hepatol Commun
. 2024 Dec;
9(1).
PMID: 39699308
Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are characterized by the destruction of the small bile ducts and the formation of multifocal biliary strictures, respectively, impairing bile flow....
3.
Gallucci G, Hayes C, Boyer J, Barbier O, Assis D, Ghonem N
Cells
. 2024 Aug;
13(15.
PMID: 39120326
Cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), result from an impairment of bile flow that leads to the hepatic retention of bile acids, causing...
4.
Zhang L, Xie P, Li M, Zhang X, Fei S, Zhao N, et al.
Hepatology
. 2024 Jul;
81(3):774-790.
PMID: 38985995
Background And Aims: Inflammatory response is crucial for bile acid (BA)-induced cholestatic liver injury, but molecular mechanisms remain to be elucidated. Solute Carrier Family 35 Member C1 (SLC35C1) can transport...
5.
Du Y, de Jong I, Gupta K, Waisbourd-Zinman O, Har-Zahav A, Soroka C, et al.
Biofabrication
. 2023 Oct;
16(1).
PMID: 37820623
Exploring the pathogenesis of and developing therapies for cholestatic liver diseases such as primary sclerosing cholangitis (PSC) remains challenging, partly due to a paucity ofmodels that capture the complex environments...
6.
Boyer J
Cell Mol Gastroenterol Hepatol
. 2023 Sep;
16(6):1033.
PMID: 37690462
No abstract available.
7.
Pan Q, Zhu G, Xu Z, Zhu J, Ouyang J, Tong Y, et al.
Cell Mol Gastroenterol Hepatol
. 2023 May;
16(2):223-242.
PMID: 37146714
Background & Aims: OATP1B3/SLCO1B3 is a human liver-specific transporter for the clearance of endogenous compounds (eg, bile acid [BA]) and xenobiotics. The functional role of OATP1B3 in humans has not...
8.
Li X, Li Y, Xiao J, Wang H, Guo Y, Mao X, et al.
Nat Commun
. 2023 Feb;
14(1):29.
PMID: 36759512
Cholangiocytes play a crucial role in bile formation. Cholangiocyte injury causes cholestasis, including primary biliary cholangitis (PBC). However, the etiology of PBC remains unclear despite being characterized as an autoimmune...
9.
Zhang L, Pan Q, Zhang L, Xia H, Liao J, Zhang X, et al.
Hepatology
. 2023 Jan;
77(6):1866-1881.
PMID: 36647589
Background And Aims: Bile acids trigger a hepatic inflammatory response, causing cholestatic liver injury. Runt-related transcription factor-1 (RUNX1), primarily known as a master modulator in hematopoiesis, plays a pivotal role...
10.
Zhao N, Zhang X, Ding J, Pan Q, Zheng M, Liu W, et al.
JCI Insight
. 2022 Aug;
7(15).
PMID: 35938531
Genetic polymorphisms are associated with the development of nonalcoholic fatty liver disease (NAFLD). Semaphorin7a (Sema7a) deficiency in mouse peritoneal macrophages reduces fatty acid (FA) oxidation. Here, we identified 17 individuals...